Psoriatic Disease: Clinical Staging.

In 2006, the introduction of the concept "psoriatic disease" (PsD) extended the traditional idea of a condition confined to skin and joints. Now we consider PsD a systemic condition, in which the increased activity of tumor necrosis factor acts as the most potent engine for a series of molecular interactions. These lead not only to the genesis of skin and joint symptoms, but also to other clinical aspects such as inflammatory bowel disease, eye involvement, and metabolic syndrome.

Third Update on Psoriatic Disease Conference: Trainee Session.

Trainee sessions have become an established feature of international conferences and were an important part of the proceedings of the Third Update on Psoriatic Disease. Presentations featured a wide range of topics from clinical, etiopathological, and therapeutic aspects of psoriatic disease and spondyloarthropathy. A selection of 7 reports from the sessions is presented here.

Psoriatic arthritis: advances in pharmacotherapy based on molecular target.

The progress on the improved understanding of disease pathogenesis and molecular biology has changed the understanding of disease profiles, emphasizing aspects that simple clinical observation could not identify, and demarcating differences between clinical pictures that seemed to overlap. An example of this spectacular evolution is represented by psoriatic arthritis (PsA). This increase of knowledge on pathogenesis has led to an important impact on therapeutic approach.